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Abstract
Objective: To investigate the expression of transglutaminases (TGs) in the ocular surface, the eyelid margin and associated
glands and to determine effect of muscarinic agents on TGs in scleral fibroblasts (SF).
Materials and Methods: Primary SFs cultured from mouse and human sclera were treated with atropine and carbachol for 5
days. Lysed cell RNA was used for real-time PCR, protein was used for Western blot analysis and TG-2 transamidase activity
was measured by ELISA. Immunohistochemistry was done to determine the expression of TGases.
Results: Immunohistochemistry and western blot confirmed the expression of TGs-1, 2, 3 and 5 proteins in cultured SFs and
eye tissues. Real time PCR showed TG-1, 2, 5 transcript levels to be down regulated 3 fold (p,0.05) in cultured human and
mouse SFs after incubation with atropine and this was reversed by carbachol. However, TG-3 expression was increased with
atropine and decreased with carbachol at all concentrations. Atropine abrogated the carbachol-induced activation of SF in a
dose-dependent manner. TGs-1, 3, 5 were localized in the entire mouse corneal epithelium, stroma and endothelium but
TG-2 was present only in the corneal subepithelium and stroma. All TGs were localized in mouse Meibomian glands
however TG-2 had a weak expression.
Conclusions: Our results confirm that TGs-1, 2, 3 and 5 are expressed in human SF and murine ocular tissues, eyelid and
associated Meibomian glands. Real-time PCR and Western blot results showed that muscarinic antagonist down-regulates
TGs-1, 2 and 5 in both cultured human and mouse SFs and upregulates TG-3. Atropine abrogated the carbachol-induced
activation of SF in a dose-dependent manner. These results suggest that manipulation of TGs by way of muscarinic receptor
acting drugs may be a plausible method of intervention in wound healing and scleral remodeling.
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Introduction
Transglutaminases (TGs) are a big class of intra- and
extracellular enzymes with at least 8 members, all of which
catalyze the formation of epsilon - (c-glutamyl) lysine isopeptide
linkages between peptide substrates. These enzymes are tightly
regulated, and are involved in processes such as inflammation, re-
epithelialization, neovascularization, synthesis and stabilization of
a fibrous extracellular matrix (ECM) [1–3].
Different types of TGs are found in various cellular compart-
ments. TG-1 is located in the cytosolic and membrane
compartments only whereas TG-2 is present in cell nucleus in
addition to cytosolic and membrane compartment. TGs-3 and 5
are restricted to the cytosolic compartment. Certain forms of TGs,
TG-4 and Factor XIII are extracellular moieties [1]. Since TGs
are found in different sub-cellular locations, it is not surprising that
they also sub-serve different functions in these locations.
Cell adhesion and cell spreading are integral functions regulated
by TGs. Primary fibroblasts from TG-2 knock out mice have
decreased adherence to culture vessels [4]. There are a few ways
that TG-2 may be involved in remodeling of ECM. First, TG-2
may affect the covalent cross-linking of ECM molecules in the
extracellular space, hence affecting stabilization and degradation
of these molecules [5,6]. Second, TG-2 may affect the motility,
adhesion and survival of the ECM producing fibroblasts, hence
influencing the amount of connective tissue molecules produced
[7,8]. Finally, TG-2 can release inactive precursors of molecules
that remodel the matrix sequestered in the matrix [9,10].
Wound healing is a dynamic process with different temporal
phases. By modifying the activity of extracellular matrix proteases,
wound healing in the damaged ocular surface may proceed in a
favorable or unfavorable manner, depending on the timing and
duration of intervention. Apoptosis in the ocular surface is not only
present in an experimental model of dry eye [11], but contributes
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18326significantly to the disease process by reducing tear secreting
components such as Goblet cells and accessory lacrimal glands.
TGs are involved in wound healing diseases such as pterygium
[12], allergic conjunctivitis [13], dry eye [14], cicatricial conjuncti-
vitis [15,16] and also in glaucoma [9,17]. In the cornea and
conjunctiva, TGs activity can be detected in the intercellular spaces,
along the basement membranes, cytoplasm of the epithelial cells,
superficial stromal keratocytes, as well as in the walls of conjunctival
stromal vessels[18].Inthe sclera, a previousstudyindicatedthatTG
activitywaslocalized tomainlytotheepiscleralvesselwalls[18].The
only TG that is well studied in ocular surface diseases, TGase-1 was
up-regulated in cicatrizing diseases and dry eye [15,16]. Although
ocular tissue and associated glands arewellinnervated bymuscarinic
cholinergic motor neurons, and carbachol a muscarinic agonist [19]
can increase TG mediated transamidation. The molecular mecha-
nism of activation and signaling pathway upstream of TGs has not
yet been elucidated in ocular surface tissues.
As a first step to understand the importance of TGs in critical
processes such as wound healing and modulation of inflammation
in ocular diseases, we aimed to investigate the expression of TGs in
the ocular surface, the eyelid margin, associated glands and their
regulation by muscarinic receptor acting drugs. In addition we
aimed to study the effects of muscarinic receptor signaling on TGs
expression in cultured cells. These expression and functional
studies will likely shed light on the pathological conditions such as
ocular surface wound healing, pterygium, cataract, glaucoma,
myopia and proliferative vitreoretinopathy.
Materials and Methods
Human and Animal Tissues
Human scleral tissues (n=6) harvested within 24 hours from
normal cadaver eyes (age range, 45–80 years) obtained at autopsy
were provided by the Singapore Eye Bank. The protocol was
approved by the Institutional Review Board of the Singapore Eye
Research Institute. All study procedures were performed as part of
standard clinical care and complied with the tenets of the
Declaration of Helsinki regarding human research, and as all
procedures performed were essential for standard clinical care of
these patients, written consent was not required, but consent was
obtained by assent. The patient’s next of kin were aware of the
privacy policy of the hospital that states that information released
for publication would not include patient identifiers.
Mice (Balb/c, n=60) were obtained from the animal holding
unit of the National University of Singapore. Approval was
obtained from the Singhealth Institutional Animal Care and Use
of Committee (IACUC; AALAC accredited, #2008/SHS/359)
and all aspects of the study were in accordance with the
Association for Research in Vision and Ophthalmology (ARVO)
recommendations for animal experimentation.
Primary Cell culture and drug treatment
Fibrous sclera (n=3 batches; 30 sclera/batch) was placed in
60 mm culture dish with dubelcco’s Modified Eagle’s Medium
(DMEM, Invitrogen-Gibco, Grand Island, NE) supplemented with
penicillin, streptomycin and amphotericin B and 10% Fetal
Bovine Serum (FBS, Invitrogen-Gibco). Tissue culture were
incubated at 37uC, 5% CO2 and allowed to reach 80%
confluence. Cells were passaged sequentially by exposing cells to
0.25% Trypsin/0.5 mM EDTA at 37uC for 5 minutes. All cells
used in experiments were below passages 3.
Passaged cells were plated at a concentration of 1610
5 into 6
well plates containing DMEM with 10% FBS. The cells were seen
to attach to the bottom of the culture wells after 4 hours. Freshly
prepared atropine and carbachol at final 0.01, 0.1, 1, 5 and 10 mM
concentrations were added for 5 days. To study the combined
Table 1. Human TGM probes and primers for qPCR reactions.
Gene Primers Sizes Prevalidated Probes
TGM 1 59 CCC CAA GAG ACT AGC AGT GG 39 (Fw)
59 AGG CCA TTC TTG ATG GAC - 39 (Rev)
84 bp # 16
TGM 2 59 AGG GTG ACA AGA GCG AGA TG - 39 (Fw)
59 TGG TCA TTC ACG ACT CCA C – 39 (Rev)
96 bp # 32
TGM 3 59 TGG AAG GAC TCT GCC ACA AT - 39 (Fw)
59 TGA GCG TAC GAG ATC TTT ATG G -39 (Rev)
137 bp # 21
TGM 5 59 GGG GAG TTC ATC CTG CTT TT -39 (Fw)
59 CTG GGG TTC ACT GTC CAA GT -39 (Rev)
191 bp # 20
doi:10.1371/journal.pone.0018326.t001
Table 2. Mouse TGM probes and primers for qPCR reactions.
Gene Primers Sizes Prevalidated Probes
TGM 1 59 GCC CTT GAG CTC CTC ATT G 39 (Fw)
59 CCC TTA CCC ACT GGG ATG AT - 39 (Rev)
74 bp # 10
TGM 2 59 GGT GAT CCT CGC TTG AGT GT - 39 (Fw)
59 CTC CAA ATC ACA CCT CTC CAG – 39 (Rev)
94 bp # 17
TGM 3 59 GAT CAC AGC TGT TTG CAA GG - 39 (Fw)
59 CAT GAG CCT GTT CCA GCA C -39 (Rev)
107 bp # 31
TGM 5 59 TCC ATC CAG CTG TCT GTG G -39 (Fw)
59 AGG GCC ACC TCT AGT CCT GT -39 (Rev)
91 bp # 26
doi:10.1371/journal.pone.0018326.t002
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atropine (0.01, 0.1, 1, 5 and 10 mM) 4 hours before being
incubated with equimolar carbachol. The culture medium was
removed and fresh medium containing the same muscarinic drug
added every day to avoid drug changes such as atropine oxidation.
Cell-lysate was collected for relative quantitative (q) PCR and
protein analysis at day 5.
Sample preparation
The cells (n=3 sets; 1610
6 cells/set) were lysed by sonification
in 16RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz,
CA) with 10 ml PMSF solution, 10 ml sodium orthovanadate
solution and 20 ml protease inhibitor cocktail solution. After
centrifugation at 20,000 6g at 4uC for 20 minutes, and the
supernatant collected. The protein content in the supernatants was
measured using the DC Protein Assay kit (Bio-Rad, Berkeley, CA)
following the manufacturer’s instructions. Samples were stored at
280uC until assayed.
Immunohistochemistry and Immunocytochemistry
The whole mouse eye, eyelid (2 months old, n=6) and human
sclera (n=3) were embedded in OCT (frozen tissue matrix)
compound at 220uC for 1 hour. Prepared tissue blocks were
sectioned with cryostat at 5 microns thicknesses and collected on
clean polysine
TM glass slides. Sections were fixed with 4% para-
formaldehyde for 10 minutes. After washing 36with 16PBS for
5 minutes, 4% goat serum diluted with 16 PBS was added as a
blocking buffer. The slides were then covered and incubated for
1 hour at room temperature (RT) in a humid chamber. After
rinsing with 16PBS, a specific primary antibody for TGs-1, 2, 3
and 5 (polyclonal raised in rabbit, Abcam, Cambridge, UK)
diluted (1:100) with 2% goat serum was added and incubated
further at 4uC in a humid chamber overnight. After washing 36
with 16 PBS for 10 minutes, fluorescein-labeled goat anti-rabbit
secondary antibody (1:200, Chemicon International, Temecula,
CA) was applied and incubated for 90 minutes at RT. After
washing and air-drying, slides were mounted with antifade
medium containing DAPI (4, 6-diamidino-2-phenylindole; Vecta-
shield; Vector Laboratories, Burlingame, CA) to visualize the cell
nuclei. Sections incubated with 2% goat serum with omitted
primary antibody were used as a control.
Fresh human and mouse SF cells were cultured on sterile
chamber slides (n=6). Cells were washed with phosphate buffered
saline (PBS) and fixed with ice-cold methanol: acetone (1:1) at 220
for 10 minutes and air-dried. Cells were permeabilised with 0.5%
Figure 1. Localization of transglutaminases (TGs) in mouse eye. (A) To determine the presence of TGs in the mouse eye, the whole eye
sections (5 microns) were stained using anti mouse TG-1, TG-2, TG-3 and TG-5 rabbit IgG-fluorescein conjugates. The negative control section was
incubated with 2% goat serum without the respective primary antibodies. Positive immunostaining of TGs were identified in the mouse cornea,
retina pigment epithelium (RPE), choroid and sclera, as compared to the negative control. The localization of TGase-2 in cornea is different from the
other 3 TGs. TG-1, TG-3, TG-5 were localized in the entire mouse corneal epithelium, stroma and endothelium but TG-2 was present only in the
corneal subepithelium (‘‘CS’’) and stroma (‘‘S) (see white arrows). Error bar=50 mM. DAPI stains nuclei (indicated by the white circles and the white
boundaries) and FITC stains cell membrane and cytoplasm. Magnification at 2006. (B) shows the localization of TG-1, TG-2, TG-3 in the mouse
palpebral (P), forniceal (F) and bulbar (B) conjunctiva but not TG-5, by immunofluorescent staining. Error bar=50 mM. DAPI stains nuclei (indicated by
white circles) and FITC stains cell membrane and cytoplasm. Magnification at 2006. (C) shows the localization of TGs in mouse meibomian glands. All
TGs were expressed in mouse meibomian glands but TG-2 was weakly detected. Error bar=50 mM. Arrow indicates the meibomian gland. DAPI stains
nuclei (indicated by white circles) and FITC stains cell membrane and cytoplasm. Magnification at 2006.
doi:10.1371/journal.pone.0018326.g001
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blocked with 1% bovine serum albumin (BSA), 0.3% Triton X-
100 in PBS for 30 minutes at RT. The cells were then processed
and stained as described before. A fluorescence microscope
(Axioplan2; Carl Zeiss Meditec, GmbH, Oberkochen, Germany)
was used to capture images. Experiments were repeated in
triplicates from 3 different samples.
Electrophoresis and Immunoblotting
Proteins in the supernatant were separated by SDS-PAGE,
transferred to nitrocellulose membranes, blocked in 5% BSA in
TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 0.0.05%
Tween-20) for 2 hours at RT, and incubated with the same anti-
TGs antibodies described above at a dilution of 1:1000 and anti b-
tubulin antibodies used as a loading control, for 1 hour at RT.
The membranes were washed 3 times in TBST and incubated
with HRP-conjugated secondary antibody (Chemicon Interna-
tional) at a dilution of 1:2500 for 1 hour at RT. Immunoreactive
bands were visualized using the enhanced chemiluminescence
method (GE Healthcare, Buckinghamshire, UK). The membrane
was wrapped in plastic and placed against an X-ray film to expose
for an appropriate length of time (30 seconds-5 minutes).
Transglutaminase Activity Assay
This assay was designed to assess the cross-linking activity of
TG-2 between two proteins. TG-2 activity was measured with
Transglutaminase colorimetric Microassay kit (TG-Covtest, Cov-
alab, Cambridge, UK). The approximate volume of reagents to
use, the wavelengths to use to read absorbance, the incubation
times were determined from previous study that have carried
experiments with similar principles [20,21]. In order to standard-
ize the protein concentration to use from the samples obtained, we
used 100 mg protein per well after several repeats with different
protein concentrations. Control and samples were subjected to
exactly the same assay procedure. All reagents used and protein
coated plates were part of the kit. Biotin cadaverine was
reconstituted with 6 ml of deionized water and 90 ml was added
into each well of the 96 well plate that comes coated with CBZ-
GLN-GLY. The rest of the steps were followed as in the
manufacturer’s instructions and finally absorbance was read at
450 nm using a microplate reader (TECAN, Austria). All
incubations were performed with gentle shaking on a laboratory
orbital shaker.
Quantitative Real-Time Comparative PCR
Total RNA was isolated from cultured human and mouse SFs
(n=3 sets; 1610
6 cells/set) using TRIzol reagent (Invitrogen life
technologies, USA) in accordance with the manufacturer’s
instructions [22]. Genomic DNA was removed by digestion with
DNase I (Amp Grade; Invitrogen-Gibco) for 15 minutes at room
temperature. One microgram of total RNA was reverse-transcribed
with random hexamers by using a first-strand cDNA synthesis kit
Figure 2. Localization of TGs in human sclera. The localization of TG-1, TG-2, TG-3 and TG-5 in the human scleral tissue with scleral staining
between the collagen fibre bundles was determined by immunofluorescent staining. No immunostaining was found in the negative control. Error
bar=50 mM. Arrow indicates the scleral fibroblasts. DAPI stains nuclei (indicated by the white circles) and FITC stains cell membrane and cytoplasm.
Magnification at 2006.
doi:10.1371/journal.pone.0018326.g002
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on an Roche 480 LightCycler Detection System (Roche Applied
Science, Mannheim, Germany) with efficiency corrected software
4.0. PCR was performed using 50 ng of cDNA of each sample. The
pre-validated hydrolysis probes for TGs-1, 2, 3 and 5 were from
human and mouse universal probe library (Roche) and the primers
for human and mouse are shown in Table 1 and 2 respectively.
GAPDH Internal Standard (Roche) was used as an endogenous
control. To standardize and evaluate scleral gene expression,
aliquots of the same cDNA (50 ng) preparation were used as
templates in all PCR reactions. The data was analyzed by
comparative CT (DDCT) method as previously described [23].
Data Analysis
Statistical comparisons between experimental groups were
conducted using Student’s t-test or one-way ANOVA (Statistica
6.0, SPSS, Chicago, IL, USA). The Mann-Whitney U-test was
used to determine differences between groups. A significance level
of p,0.05 was used. Data are presented as means 6 standard
deviation.
Results
Expression of TGs in the Ocular Surface and associated
glands
Positive immunostaining of TGs was shown in the mouse eye
tissues (Figure 1A). This finding is useful for our understanding of
the gene expression of TGs in mouse eye development. TGs-1, 3,
5 were localized in the entire mouse corneal epithelium, stroma
and endothelium but TG-2 was present only in the corneal
subepithelium and stroma. All TGs showed staining in the RPE,
choroid and sclera, with scleral staining between the collagen fibre
bundles. No immunostaining was observed in the sections
incubated with 2% goat serum and DAPI stains the nucleus.
Figure 3. Expression of TGs in mouse and human scleral fibroblasts. (A) The cultured mouse scleral fibroblasts expressed all 4 TGs at cellular
level. TG-1, TG-3 and TG-5 were located in the cytosolic and membrane compartments only whereas TG-2 was present in cell nucleus along with
cytosolic and membrane compartment. Error bar=50 mM. Magnification at 2006. (B) The cultured human scleral fibroblasts expressed all 4 TGs at
cellular level. TG-1, TG-3 and TG-5 were located in the cytosolic and membrane compartments only whereas TG-2 was present in cell nucleus along
with cytosolic and membrane compartment. Error bar=50 mM. Magnification at 2006.
doi:10.1371/journal.pone.0018326.g003
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in the mouse palpebral, forniceal and bulbar conjunctiva but not
TG-5 (Figure 1B). All these TGs were expressed in mouse
meibomian glands (Figure 1C) but TG-2 was weakly detected.
Positive immunostaining of TGs was shown in the human
scleral tissues (Figure 2). Primary cultured mouse and human SFs
expressed all 4 TGs (Figure 3A and B respectively). TGs-1, 3 and 5
were located in the cytosolic and membrane compartments only
whereas TG-2 was present in cell nucleus along with cytosolic and
membrane compartment.
Confirmation of TG proteins in mouse and human scleral
fibroblasts
Western blot was carried out in the cultured mouse and human
SF to confirm the expression of TGs at protein level and ß-tubulin
was used as a loading control (Figure 4).
Figure 4. Confirmation of TG proteins by Western blot analysis. Western blot confirmed the expression of TG-1, TG-2, TG-3 and TG-5 proteins
in mouse and human scleral fibroblasts. ß-tubulin was used as a loading control. TG-1: 90 kDa, TG-2: 82 kDa, TG-3: 77 kDa, TG-5: 80 kDa and ß-tubulin
(loading control): 55 kDa.
doi:10.1371/journal.pone.0018326.g004
Figure 5. Effect of atropine treatment on TGs in mouse and human scleral fibroblasts. (A) Western blot image detecting TG proteins in
mouse scleral fibroblasts after atropine treatment. P2 cultured mouse scleral fibroblasts were treated with atropine at concentrations of 0.01 mM,
0.1 mM, 1 mM, 5 mM and 10 mM for 5 days. Following 5 days of treatment, the total cellular protein was extracted from these cells and TG proteins
detected via Western blot analysis. It can be observed that the TG-1, 2 and 5 protein levels were reduced after atropine treatment. However, TG-3
protein level was increased after receiving atropine. ß-tubulin was used as a loading control. (B) Western blot image detecting TG proteins in human
scleral fibroblasts after atropine treatment. P2 cultured human scleral fibroblasts were treated with atropine at concentrations of 0.01 mM, 0.1 mM,
1 mM, 5 mM and 10 mM for 5 days. Following 5 days of treatment, the total cellular protein was extracted from these cells and TG proteins detected via
Western Blot analysis. It can be observed that the TG-1, 2 and 5 protein levels were reduced after atropine treatment. However, TG-3 protein level was
increased after receiving atropine. ß-tubulin was used as a loading control.
doi:10.1371/journal.pone.0018326.g005
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The mouse and human SFs were treated with atropine or
carbachol at 0.01, 0.1, 1, 5 and 10 mM concentrations for 5 days.
Following 5 days of treatment, the total cellular protein was
extracted from these cells and TG proteins detected via Western
blot analysis. After atropine treatment in both mouse and human
SFs, the TGs-1, 2 and 5 protein levels were reduced (Figure 5A
and 5B respectively) and the converse was true with carbachol
treatment (Figure 6A and 6B respectively). However, TG-3
protein level was increased in both mouse and human SFs after
receiving atropine (Figure 5A and 5B respectively) and the
converse observed with carbachol (Figure 6A and 6B respectively).
These results were similar to changes in transcript levels.
Transglutaminase-2 activity
The TG-2 colorimetric assay serves as a high throughput and
quantitative assay to assess transamidase activity. The mouse SF
treated with carbachol and atropine at 0.01, 0.1, 1, 5 and 10 mM
for 5 days. The mouse and human SFs treated with carbachol
increased the transamidase activity (Figure 7) of endogenous
cellular TG-2 but this activity was reduced by atropine treatment
in a concentration-dependent manner.
Quantification of TGs mRNA expression level
P2 cultured mouse and human SFs were treated with atropine
or carbachol at different concentrations for 5 days. Following 5
days of treatment, the total RNA was extracted from these cells
and TGs transcript level was quantified via real-time qPCR
analysis. The TGs-1, 2 and 5 transcript levels were down regulated
after receiving atropine in both mouse and human SF at all
concentrations (Figures 8A and 8B respectively). However, TG-3
transcript was up regulated in the atropine treated cells. The
opposite findings were observed with carbachol treatment in both
cells for TG-2 and TG-3 at all concentrations. However, TGs-1
and 5 were increased only by relatively higher concentrations of
carbachol (Figures 9A and 9B respectively). Atropine abrogated
the carbachol-induced activation of TGs-1,2,3,5 in a dose-
dependent manner when mouse and human SFs (Figure 10A–H
respectively) were pre-treated with atropine 4 hours before being
incubated with equimolar carbachol.
Discussion
In our study, we found that distinct subtypes of the TGs
displayed differential expression in various eye tissues. The
localization and expression of TG-2 vary within ocular tissues.
TG-2 expression was in the basal layer of cornea and conjunctival
epithelium, the basal lamina and in the stroma of these tissues.
However, TG-1 and 3 were expressed in the entire thickness of
cornea and conjunctival epithelium. The expression of TG-2 in
the cornea is different from the other 3 TGs. Components of
epithelial basement membranes and dermo-epidermal complexes
Figure 6. Effect of carbachol treatment on TGs in mouse and
human scleral fibroblasts. (A) Western blot image detecting TG
proteins in mouse scleral fibroblasts after carbachol treatment. P2
cultured SFs were treated with carbachol at different concentrations for
5 days. Following 5 days of treatment, the total cellular protein was
extracted from these cells and TGs proteins detected via Western blot
analysis. After carbachol treatment in both SFs, the TGs-1, 2 and 5
protein levels were increased. However, TG-3 protein level was
decreased after receiving carbachol. ß-tubulin was used as a loading
control. (B) Western Blot image detecting TG proteins in human scleral
fibroblasts after carbachol treatment. P2 cultured human scleral
fibroblasts were treated with carbachol at concentrations of 0.01 mM,
0.1 mM, 1 mM, 5 mM and 10 mM for 5 days. Following 5 days of
treatment, the total cellular protein was extracted from these cells and
TG proteins detected via Western blot analysis. It can be observed that
the TG-1, TG-2 and TG-5 protein levels were increased after carbachol
treatment. However, TG-3 protein level was decreased after receiving
carbachol. ß-tubulin was used as a loading control.
doi:10.1371/journal.pone.0018326.g006
Figure 7. Transamidase activity of TG-2 with stimulation of
atropine and carbachol in scleral fibroblasts. Line graph
illustrating the results of the transamidase activity of TG-2 in 100 mg
of protein lysate from mouse and human cultured scleral fibroblasts.
Values were normalized against control values. The mouse and human
scleral fibroblasts treated with carbachol and atropine at 0.01, 0.1, 1, 5
and 10 mM for 5 days. The SF treated with carbachol increased the
transamidase activity of endogenous cellular TG-2 but this activity was
reduced by atropine treatment in a concentration-dependent manner.
The values represented the means of three independent samples and
error bars represent standard deviation, n=3, *p,0.05, **p,0.01.
Straight lines represent the mouse SF and dashed lines represent the
human SF. Open markers are atropine treated and closed markers are
carbachol treated SF cells.
doi:10.1371/journal.pone.0018326.g007
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18326Figure 8. Effect of carbachol on TGM mRNA expression in mouse scleral fibrobalsts. Bar chart illustrating the results of TGM mRNA
expression levels of mouse scleral fibroblasts following with stimulation of carbachol. P2 cultured mouse scleral fibroblasts were treated with atropine
or carbachol at different concentrations of 0.01 mM, 0.1 mM, 1 mM, 5 mM and 10 mM for 5 days. Following 5 days of treatment, the total RNA was
extracted from these cells and TGM transcript level was quantified via qPCR analysis. Height of bars show the means of three independent samples
and error bars represent standard deviation. Values are normalized against GAPDH house keeping genes. The TGM-1, 2 and 5 transcript levels were
down regulated after receiving atropine (A, B and D respectively) at all concentrations. However, TGM-3 transcript was upregulated in the atropine
treated cells (C). The opposite findings were observed with carbachol treatment in both TGM-2 (E) and TGM-3 (F) at all concentrations. However,
TGM-1 and 5 were increased only by relatively higher concentrations of carbachol (G and H respectively).
doi:10.1371/journal.pone.0018326.g008
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the epithelial basement membranes. This explains that TG-2
could interact with the hemidesmosomal proteins integrin a6b4,
BP180/collagen XVII, the microfibril components fibrillin 1 and
microfibril-associated glycoprotein precursor (MAPG1), which
may be cross linked by TG-2 transamidation activity or may be
involved in alternate splicing. Hence, key molecules that can
regulate extracellular matrix and modulate wound healing might
be modified by TG-2 in cornea.
TG-5 expression was not found in the mouse conjunctiva and
expressed in the whole corneal epithelium, whereas TG-2
expression was relatively weak in the meibomian glands,
compared to other TGs. Immunohistochemical staining showed
all 4 TGs to be distributed evenly throughout the sclera. As
immunolabelling is limited between the collagen fibre bundles, it is
likely that the TGs are localized to the scleral fibroblast processes.
This was confirmed by the presence of all 4 TGs in cultured scleral
fibroblasts. To the best of our knowledge this appears to be the first
report characterizing distributions of TGs in the mouse ocular
tissues and in the human sclera.
Previous studies have reported that TG-2 was associated with
epithelia and particularly with connective tissue of human and
monkey cornea. TG-1 was restricted to the corneal epithelium and
TG-3 was absent; however TG-3 was present in the cytoplasm of
the granular layer cells of human skin [24]. The distribution of the
TGs reported here was different from our results for the mouse eye
tissues. These observations may represent real differences in the
distribution of corneal TGs between species or alternatively,
differences in antibody specificities.
In the monkey cornea and conjunctiva, TG activity can be
detected in the intercellular spaces, along the basement mem-
branes, the cytoplasm of the epithelial cells, the superficial stromal
keratocytes, as well as in the walls of the conjunctival stromal
vessels [24]. Although TG-2 can be found within various ocular
cell types, TG-1 was identified only in the corneal epithelium, in
the suprabasal cells. In our current study we have carried out TGs
expression studies in the SF cells and we would be exploring this
further using wound healing models in animals.
A study in rats [25] and other studies have confirmed the role
of retinoic acid in the expression of TG-1 [26] and TG-2 [27].
Because TG-1 has a role in ocular surface keratinization, some
studies have focused on other upstream triggers of TG-1
including interferon gamma (IFN-c) [28]. IFN-c was found to
be involved in the ocular surface keratinization of patients with
Sjogren’s syndrome [29], supporting the importance of the IFN-
c-TG-1 pathway in the ocular surface pathology. TG-2, a multi-
functional tissue enzyme of the transglutaminase family, plays a
central role in wound healing, apoptosis and ECM production
[1]. The kinetics and distribution of TG-2 in the ocular surface
were similar to that in dermal wound healing. Early in the
healing process, the TG-2 elevation was noted in migrating
keratinocytes and infiltrating macrophages, and later, limited to
the dermoepidermal junction [5,6]. This similarity in the wound
healing between the ocular surface and skin is important because
a large body of literature exists on the role of TG in the in-vivo
wound healing of the skin, such as those after ultraviolet radiation
[30,31].
In various studies, TG-2 has also been implicated in the
signaling pathways of extracellular matrix molecules such as
fibronectin and collagen subtypes [32]. Cell adhesion and cell
spreading are integral functions regulated by TGs. Primary
fibroblasts from TG-2 knock out mice have decreased adherence
to culture vessels [33]. Cell-matrix interactions are critical for
spreading and migration of cells, as well as the organization of
extracellular matrix [34]. In the cornea epithelium for example,
TG is involved in the regulation of cornified envelope proteins and
apoptosis [35]. In the rat cornea [25], TG-2 was strongly up
regulated in the early wound healing process and actively
migrating cornea epithelial cells were expressing TG-2.
Anti-muscarinic drugs were able to change collagen and other
structural molecules in animal models of myopia [36,37],
establishing a link to scleral connective tissue in these pathways.
However, even though muscarinic receptor subtypes may be
involved in scleral remodeling, we do not know the intermediate
and downstream target molecules. Our present study that showed
atropine decreased TGs-1, 2 and 5 proteins and carbachol
increased. However, for unknown reasons, these drugs have the
opposite effect on TG-3 protein expression. Moreover, atropine
abrogated the carbachol-induced activation of SF in a dose-
dependent manner.
In fibroblasts cultured from scleral explants, treatment with
atropine induced a reduction in the level of TG-2 protein and
mRNA. Previous investigation showed that TG activity increased
after agonistic stimulation [19]. This suggests that manipulation of
TG through muscarinic receptor may be a plausible method of
intervention in scleral remodeling and human diseases such as
myopia, which involved scleral remodeling [37].
In the eye, researchers are beginning to appreciate the
importance of TGs in the ocular surface, anterior and posterior
segment diseases [38,39]. Taking advantage of the understanding
of TGs in critical processes such as wound healing and modulation
of inflammation, translational research in ocular diseases will be
greatly enhanced, including ocular surface diseases, glaucoma,
cataract and proliferative vitreoretinopathy. It is important to
know that drugs have different effects on different TGs, because
some functions are more sub-served by one TG than another.
Kalinin et al [40] reported that cornified envelope assembly occurs
by passing substrates from TG-5 to TG-3 to TG-1, so it may be
possible to manipulate specific TG and not others. However, in
view of functional redundancy, what is not clear is how different
TGs can compensate for one another since all of them have
transamidase activity. In addition, only TG-2 has G protein
activity, G protein function may be a preferred treatment target in
wound healing and not the transamidase.
In conclusion, our results confirm that TGs-1, 2, 3 and 5 are
expressed in ocular tissues and associated glands. Real-time qPCR
and Western blot results showed that muscarinic antagonist down-
regulates TGs-1, 2 and 5 in both cultured mouse and human SFs.
However, TG-3 was up regulated in the atropine treated cells. The
opposite findings were observed with carbachol treatment in both
cells for TGs-1, 2, 5 and 3. Atropine abrogated the carbachol-
Figure 9. Effect of atropine on TGM mRNA expression in human scleral fibroblasts. P2 cultured human SFs were treated with atropine at
different concentrations for 5 days. Following 5 days of treatment, the total RNA was extracted from these cells and TGM transcript level was
quantified via qPCR analysis. Height of bars show the means of three independent samples and error bars represent standard deviation. Values are
normalized against GAPDH house keeping genes. The TGM-1, 2 and 5 transcript levels were down regulated after receiving atropine (A, B and D
respectively) at all concentrations. However, TGM-3 transcript was upregulated in the atropine treated cells (C). The opposite findings were observed
with carbachol treatment in both TGM-2 (E) and TGM-3 (F) at all concentrations. However, TGM-1 and 5 were increased only by relatively higher
concentrations of carbachol (G and H respectively).
doi:10.1371/journal.pone.0018326.g009
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PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18326induced activation of SF in a dose-dependent manner. These
results suggest that manipulation of TGs by way of muscarinic
receptor acting drugs may be a plausible method of intervention in
wound healing and scleral remodeling.
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